SCHEMBL19862002

SCHEMBL19862002

O=C(Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1cc(Cl)ccc1OP(=O)(OO)OO

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX1 P51575 11/20 0.62
TMPRSS4 Q9NRS4 9/20 0.62
P2RX7 Q99572 8/20 0.62
P2RX4 Q99571 7/20 0.62
MEN1 O00255 2/20 0.62
KMT2A Q03164 2/20 0.62
IKBKB O14920 1/20 0.62
CHUK O15111 1/20 0.62
KDR P35968 1/20 0.62
FLT3 P36888 1/20 0.62
MYLK Q15746 1/20 0.62
MAP4K5 Q9Y4K4 1/20 0.62
TLR8 Q9NR97 1/20 0.55
CYP1A2 P05177 1/20 0.51
POLB P06746 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
SLC2A1 P11166 1/20 0.50
XPO1 O14980 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16702757 0.94 P2RX1 (0.67) P2RX1TMPRSS4P2RX7P2RX4MEN1
SCHEMBL19862000 0.90 P2RX1 (0.61) P2RX1TMPRSS4P2RX7P2RX4MEN1
SCHEMBL6102085 0.88 P2RX1 (0.65) P2RX1TMPRSS4P2RX7P2RX4MEN1
SCHEMBL19604001 0.88 TMPRSS4 (0.59) P2RX1TMPRSS4P2RX7P2RX4MEN1
SCHEMBL16703449 0.87 P2RX1 (0.64) P2RX1TMPRSS4P2RX7P2RX4MEN1
SCHEMBL29511638 0.87 P2RX1 (0.64) P2RX1TMPRSS4P2RX7P2RX4MEN1
SCHEMBL28359923 0.87 P2RX1 (0.64) P2RX1TMPRSS4P2RX7P2RX4MEN1
Potassium Ion SCHEMBL29511655 0.86 P2RX1 (0.62) P2RX1TMPRSS4P2RX7P2RX4MEN1
SCHEMBL28359764 0.85 P2RX1 (0.61) P2RX1TMPRSS4P2RX7P2RX4MEN1
SCHEMBL28359926 0.85 P2RX1 (0.61) P2RX1TMPRSS4P2RX7P2RX4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10894055-B2 Pharmaceutical compositions, methods of making pharmaceutical compositions, and kits comprising 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}4-chlorophenyl dihydrogen phosphate AEROMICS, INC. (US) 2021-01-19 US disclosed
US-20190307779-A1 NOVEL FORMULATIONS AEROMICS, INC. (US) 2019-10-10 US disclosed
US-20180042873-A1 NOVEL METHODS AEROMICS, INC. (US) 2018-02-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180042873-A1 NOVEL METHODS AQP4, AQP1, AQP3 P2RX1 2332/4885TMPRSS4 2568/4885P2RX7 2547/4885
US-20190307779-A1 NOVEL FORMULATIONS DCPS, PRCP, DCTPP1 P2RX1 1115/4885TMPRSS4 228/4885P2RX7 778/4885
US-10894055-B2 Pharmaceutical compositions, methods of making pharmaceutical compositions, and kits comprising 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}4-chlorophenyl dihydrogen phosphate PLCG2, DCPS, DCTPP1 P2RX1 641/4885TMPRSS4 1279/4885P2RX7 322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.